Investor: Biotech Company Concealed Gene Therapy Treatment Shortcomings

(January 20, 2017, 11:54 AM EST) -- NEW YORK — A biotechnology company and certain of its executive officers concealed from investors that the science company’s gene replacement therapy drug was not viable and that the company’s principal...
To view the full article, register now.